The iron chelator deferasirox protects mice from mucormycosis through iron starvation
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Mucormycosis causes mortality in at least 50% of cases despite current first-line therapies. Clinical and animal data indicate that the presence of elevated available serum iron predisposes the host to mucormycosis. Here we demonstrate that deferasirox, an iron chelator recently approved for use in humans by the US FDA, is a highly effective treatment for mucormycosis. Deferasirox effectively chelated iron from Rhizopus oryzae and demonstrated cidal activity in vitro against 28 of 29 clinical isolates of Mucorales at concentrations well below clinically achievable serum levels. When administered to diabetic ketoacidotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decreased tissue fungal burden, with an efficacy similar to that of liposomal amphotericin B. Deferasirox treatment also enhanced the host inflammatory response to mucormycosis. Most importantly, deferasirox synergistically improved survival and reduced tissue fungal burden when combined with liposomal amphotericin B. These data support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of mucormycosis with current therapy. As iron availability is integral to the pathogenesis of other infections (e.g., tuberculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This pathway appears to be partly responsible for the beneficial clinical effects of iron chelators observed in several experimental infection systems (Mencacci et al., 1997; Fritsche et al., 2001; Ibrahim et al., 2007; Bellmann-Weiler et al., 2013; Nairz et al., 2013).”
From Iron at the interface of immunity and infection (2014) · cites this paper as Ibrahim et al., 2007
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, the Fe chelator desferasirox, which cannot be used by molds to acquire Fe, improves survival of infected mice, limiting Fe availability to the pathogen while enhancing host resistance mechanisms [238].”
From The Iron age of host–microbe interactions (2015) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Novel perspectives on mucormycosis: pathophysiology, presentation, and management
Spellberg, B., Edwards, J., & Ibrahim, A. (2005) · Clinical Microbiology Reviews · doi:10.1128/cmr.18.3.556-569.2005 · Cited by 1,537
Self-citationEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Schaible, U. E., & Kaufmann, S. H. E. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro1046 · Cited by 945
Cappellini, M. D. (2006) · Blood · doi:10.1182/blood-2005-08-3430 · Cited by 717 · cited 2×
“Furthermore, it is known that deferasirox chelation is specific for iron and that other trace metals and cations are not affected by the drug (27, 28).”
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Artis, W. M., Fountain, J. A., Delcher, H. K., & Jones, H. E. (1982) · Diabetes · doi:10.2337/diabetes.31.12.1109 · Cited by 369 · cited 2×
“Alternatively, the enhanced efficacy of deferasirox in the diabetic ketoacidotic mouse model might reflect the ability of this iron chelator to efficiently chelate serum iron previously freed by proton-mediated dissociation from iron-sequestering proteins (2, 16, 17).”
Boelaert, J. R., de Locht, M., Van Cutsem, J., Kerrels, V, Cantinieaux, B., Verdonck, A., Van Landuyt, H. W., & Schneider, Y. J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116419 · Cited by 340 · cited 2×
“The potential therapeutic role of iron chelation therapy for mucormycosis was initially obscured by the paradoxically increased risk of developing mucormycosis during treatment with deferox-amine (18).”
Research works printed but not linked: 4
- Ganz, 2006, Curr. Top. Microbiol. Immunol., 306, 183
- Artis, 1982, Diabetes., 31, 1109, 10.2337/diacare.31.12.1109 · doi:10.2337/diacare.31.12.1109 · Paper page
- Fu, 2004, FEMS Microbiol. Lett., 235, 169
- Ibrahim, A.S., et al. 2000. Comparison of amphotericin B and amphotericin B lipid complex in the treatment of murine-induced zygomycosis. In 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17–20. Toronto, Ontario, Canada. American Society of Microbiology. Abstract 1681.
Cited by
Items 101–200 of 327
Root Causes of Fungal Coinfections in COVID-19 Infected Patients
Amin, A., Vartanian, A., Poladian, N., Voloshko, A., Yegiazaryan, A., Al-Kassir, A. L., & Venketaraman, V. (2021) · Infectious Disease Reports · doi:10.3390/idr13040093 · Cited by 52
“oryzae as xinosideriphores, and thus, would further predispose patients to Mucormycosis [69,70,71].”
BackgroundSymeonidis, A. S., & Marangos, M. N. (2012) · InTech eBooks · doi:10.5772/34760 · Cited by 54
Rare fungal infectious agents: a lurking enemy
Skiada, A., Pavleas, I., & Drogari‐Apiranthitou, M. (2017) · F1000Research · doi:10.12688/f1000research.11124.1 · Cited by 53
Seifert, M., Nairz, M., Schroll, A., Schrettl, M., Haas, H., & Weiss, G. (2008) · Immunobiology · doi:10.1016/j.imbio.2008.07.010 · Cited by 51
“…increased iron availability in the body has been shown to be associated with an increased risk for aspergillosis (Kontoyiannis et al., 2007), while iron restriction strategies upon application of iron chelators have been proven to be effective in murine models of zygomycosis (Ibrahim et al., 2007).”
BackgroundLewis, R. E., Albert, N. D., & Kontoyiannis, D. P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03569-14 · Cited by 51
“However, very limited in vivo preclinical data exist to suggest which combination therapy would be most effective or which antifungal should be added for a patient who may have less than optimal concentrations (29).”
BackgroundManagement of Invasive Infections in Diabetes Mellitus: A Comprehensive Review
Khanam, A., Hithamani, G., Jayapala, N., Pradeep, S. R., Barman, S., & Srinivasan, K. (2023) · Biologics · doi:10.3390/biologics3010004 · Cited by 51
ATP Exhibits Antimicrobial Action by Inhibiting Bacterial Utilization of Ferric Ions
Tatano, Y., Kanehiro, Y., Sano, C., Shimizu, T., & Tomioka, H. (2015) · Scientific Reports · doi:10.1038/srep08610 · Cited by 51
Agents of Mucormycosis and Entomophthoramycosis
Kontoyiannis, D. P., & Lewis, R. E. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00260-5 · Cited by 51
Zygomycosis and diabetes mellitus
Lanternier, F., & Lortholary, O. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02975.x · Cited by 51
“Another recent chelator, deferasirox (Exjade), was also effective (as measured by time to death/fungal burden) in ketoacidotic mice, was synergistic with LAmB, and increased the inflammatory response [34,35].”
BackgroundSeike, K., Kiledal, E. A., Fujiwara, H., Henig, I. J., da Silva, M. B., van den Brink, M. R. M., Hein, R., Hoostal, M. J., Liu, C., Oravecz-Wilson, K. I., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.01.007 · Cited by 49
Puri, S., Kumar, R., Rojas, I. G., Salvatori, O., & Edgerton, M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02152-18 · Cited by 48
“(21) as well as synergy with antifungals against Cryptococcus neoformans in vitro (22).”
BackgroundTransferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections
Bruhn, K. W., & Spellberg, B. (2015) · Current Opinion in Microbiology · doi:10.1016/j.mib.2015.07.005 · Cited by 48
Self-citationIleocolonic mucormycosis in adult immunocompromised patients: A surgeon’s perspective
Lo, O. S., & Law, W.-L. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i9.1165 · Cited by 47
Roilides, E., Antachopoulos, C., & Simitsopoulou, M. (2014) · Mycoses · doi:10.1111/myc.12236 · Cited by 46
Host‐iron assimilation: pathogenesis and novel therapies of mucormycosis
Ibrahim, A. S. (2014) · Mycoses · doi:10.1111/myc.12232 · Cited by 46
Self-citationStanford, F. A., & Voigt, K. (2020) · Genes · doi:10.3390/genes11111296 · Cited by 47
Kousser, C., Clark, C., Sherrington, S. L., Voelz, K., & Hall, R. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-42175-0 · Cited by 44
How to treat fungal infections in ICU patients
Matthaiou, D. K., Christodoulopoulou, T. C., & Dimοpoulos, G. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0934-8 · Cited by 44
“found to be highly fungicidal in animal models [73].”
BackgroundAntifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases
Petzer, V., Theurl, I., & Weiß, G. (2018) · Pharmaceuticals · doi:10.3390/ph11040135 · Cited by 43
“Thus, depending on the underlying disease, iron supplementation could have disease modifying effects through its regulatory effects on the immune function [44,202].”
BackgroundNeupane, G. P., & Kim, D. (2009) · Transfusion · doi:10.1111/j.1537-2995.2009.02186.x · Cited by 42
“enterocolitica septicemia and Mucorales.(10,20,22) They are also susceptible to V.”
BackgroundPomorska, A., Małecka, A., Jaworski, R., Radoń‐Proskura, J., Hare, R. K., Nielsen, H. V., Andersen, L. O., Jensen, H. E., Arendrup, M. C., & Irga‐Jaworska, N. (2018) · Mycopathologia · doi:10.1007/s11046-018-0287-0 · Cited by 42
Controversies on the Consequences of Iron Overload and Chelation in MDS
Vinchi, F., Hell, S., & Platzbecker, U. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000357 · Cited by 42
“Whereas the use of deferoxamine in infections has to be avoided, because of its action as a siderophore promoting pathogen growth, patients treated with deferasirox does not increase the incidence of infections andhasbeen suggested as potential adjunct therapy in patients with mucormycosis.(81,82)”
BackgroundCombination therapy with iron chelation and vancomycin in treating murine staphylococcemia
Luo, G., Spellberg, B. J., Gebremariam, T., Lee, H., Xiong, Y. Q., French, S. W., Bayer, A. S., & Ibrahim, A. S. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2023-5 · Cited by 42
“Importantly, Def demonstrates a time-dependent, rather than concentration-dependent, killing activity [16].”
Self-citationDogra, S., Arora, A., Aggarwal, A., Passi, G., Sharma, A., Singh, G., & Barnwal, R. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.794176 · Cited by 41
Kontoghiorghe, C., Kolnagou, A., & Kontoghiorghes, G. J. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.787408 · Cited by 41
“Encouraging findings were also reported for the possible use of L1 and DFRA in mucormycosis patients which is a very serious and sometimes fatal infection and for which there is no effective treatment for many patients at present [113,114].”
Diabetic murine models for Acinetobacter baumannii infection
Luo, G., Spellberg, B. J., Gebremariam, T., Bolaris, M., Lee, H., Fu, Y., French, S. W., & Ibrahim, A. S. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks050 · Cited by 41
Self-citationDeferasirox-loaded pluronic nanomicelles: Synthesis, characterization, in vitro and in vivo studies
Rahdar, A., Hajinezhad, M. R., Sargazi, S., Barani, M., Bilal, M., & Kyzas, G. Z. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114605 · Cited by 40
Hsu, J. L., Manouvakhova, O. V., Clemons, K. V., Inayathullah, M., Tu, A. B., Sobel, R. A., Tian, A., Nazik, H., Pothineni, V. R., Pasupneti, S., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2616 · Cited by 38
“Cultures were grown at 37°C on PDA plates containing 1 mM ascorbate (Sigma-Aldrich) and 1 mM ferrozine (Sigma-Aldrich) (31).”
BackgroundMethodInfluentialIron starvation induces apoptosis in rhizopus oryzae in vitro
Shirazi, F., Kontoyiannis, D. P., & Ibrahim, A. S. (2015) · Virulence · doi:10.1080/21505594.2015.1009732 · Cited by 38
“The higher rate of infection by R. oryzae in patients with elevated levels of free iron in serum highlights the central role of iron metabolism in the fungal pathogenesis.5 Ibrahim et al.1 found that the iron chelator deferasirox, unlike the deferoxamine, does not act as an iron siderophore for Rhizopus.”
BackgroundMethodResultSelf-citationSahu, R. K., Salem-Bekhit, M. M., Bhattacharjee, B., Almoshari, Y., Ikbal, A. M. A., Alshamrani, M., Bharali, A., Salawi, A., Widyowati, R., Alshammari, A., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10091079 · Cited by 38
“Various researchers have demonstrated that iron chelation therapy with deferasirox or deferiprone prevents mucormycosis in mice with diabetic ketoacidosis and promotes longevity, whereas adjunctive deferasirox was both effective and tolerated in an open-label study of eight cases of mucormycosis [62,63].”
BackgroundLax, C., Navarro-Mendoza, M. I., Arques, C. P., Navarro, E., Nicolás, F. E., & Garre, V. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100124 · Cited by 38
“The complementation of uracil auxotrophy has been extensively used as a selective marker in the transformation of other fungi, including Mucorales (Gutiérrez et al., 2011; Ibragimova et al., 2020; Ibrahim et al., 2007; Nosheen et al., 2021).”
BackgroundAnimal Models to Study Mucormycosis
Jacobsen, I. D. (2019) · Journal of Fungi · doi:10.3390/jof5020027 · Cited by 38
“results; sacrificing some animals shortly after infection to determine the spore number in pulmonary tissue can be useful to ensure the reproducibility and to determine the effective infectious dose [35,36].”
BackgroundLaskaris, P., Atrouni, A., Calera, J. A., d'Enfert, C., Munier-Lehmann, H., Cavaillon, J.-M., Latgé, J.-P., & Ibrahim-Granet, O. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00324-16 · Cited by 37
“Deferiprone and deferasirox have been 402 successfully used to treat mucormycosis and aspergillosis in mice (61) (62) (63, 64) and 403”
BackgroundSoummer, A., Mathonnet, A., Scatton, O., Massault, P. P., Paugam, A., Lemiale, V., Mira, J. P., Dannaoui, É., Cariou, A., & Lortholary, O. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01611-07 · Cited by 37
“New iron chelators have recently been reported to be successful experimentally (3) and in a patient with refractory zygomycosis (5, 7).”
BackgroundInfluentialMucormycosis: A triple burden in patients with diabetes during COVID-19 Pandemic
Fathima, A. S., Mounika, V. L., Kumar, V. U., Gupta, A. K., Garapati, P., Ravichandiran, V., Dhingra, S., & Murti, K. (2021) · Health Sciences Review · doi:10.1016/j.hsr.2021.100005 · Cited by 36
Manzoori, J. L., Jouyban, A., Amjadi, M., Panahi‐Azar, V., Tamizi, E., & Gharamaleki, J. V. (2010) · Luminescence · doi:10.1002/bio.1218 · Cited by 36
The impact of mucormycosis (black fungus) on SARS-CoV-2-infected patients: at a glance
Islam, M. R., Rahman, M. M., Islam, M. R., Sarkar, N., Akash, S., Islam, M., Islam, F., Aktar, M. N., Saeed, M., Harun-Or-Rashid, M., et al. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22204-8 · Cited by 35
Saunders, I. M., Tan, M., Koura, D. T., & Young, R. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2443 · Cited by 32
Mucormycosis in the COVID-19 Environment: A Multifaceted Complication
Sharma, R., Kumar, P., Rauf, A., Chaudhary, A., Prajapati, P., Emran, T. B., Lima, C. M. G., & Conte‐Júnior, C. A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.937481 · Cited by 32
Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review
Meena, D. S., Kumar, D., & Bohra, G. K. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101332 · Cited by 32
“first discussed the fungicidal activity of deferasirox against Mucorales in an in vitro study [44].”
BackgroundAttenuation of acute and chronic liver injury in rats by iron-deficient diet
Otogawa, K., Ogawa, T., Shiga, R., Nakatani, K., Ikeda, K., Nakajima, Y., & Kawada, N. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00735.2007 · Cited by 31
“In particular, the clinical use of ICL670 (deferasirox), an orally administrable Fe(3) -chelator, in hepatic iron overload is now awaited (14, 16).”
BackgroundEditorial Commentary:What is the Role of Combination Therapy in Management of Zygomycosis?
Walsh, T. J., & Kontoyiannis, D. P. (2008) · Clinical Infectious Diseases · doi:10.1086/589858 · Cited by 32
TIME COURSE OF IRON METABOLISM IN CRITICALLY ILL PATIENTS
Piagnerelli, M., COTTON, F. J., Herpain, A., Rapotec, A., Chatti, R., Gulbis, B., & Vincent, J.-L. (2013) · Acta Clinica Belgica · doi:10.2143/acb.68.1.2062715 · Cited by 31
Mucormycosis, Pseudallescheriasis, and Other Uncommon Mold Infections
Quan, C., & Spellberg, B. J. (2010) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200906-033al · Cited by 31
Self-citationHosogaya, N., Miyazaki, T., Nagi, M., Tanabe, K., Minematsu, A., Nagayoshi, Y., Yamauchi, S., Nakamura, S., Imamura, Y., Izumikawa, K., et al. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12043 · Cited by 28
“…fungi, such as C. albicans, A. fumigatus, C. neoformans, and Rhizopus oryzae, suggest the potential use of iron chelators in antifungal therapy (Ibrahim et al., 2006, 2007; Prasad et al., 2006; Zarember et al., 2009; Fiori & Van Dijck, 2012; Kim et al., 2012), although the adverse effects of…”
BackgroundActivity of Deferasirox in Mucorales : Influences of Species and Exogenous Iron
Lewis, R. E., Pongas, G. N., Albert, N. D., Ben‐Ami, R., Walsh, T. J., & Kontoyiannis, D. P. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00792-10 · Cited by 29
“Deferasirox, a tridentate iron chelator used for the treatment of iron-overloaded patients, has shown potential as a therapeutic intervention for mucormycosis (8).”
BackgroundMethodResultInfluentialIron overload and allogeneic hematopoietic stem-cell transplantation
Kanda, J., Kawabata, H., & Chao, N. J. A. (2011) · Expert Review of Hematology · doi:10.1586/ehm.10.81 · Cited by 28
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs
Meagher, R. B., Lewis, Z., Ambati, S., & Lin, X. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114776 · Cited by 27
Şıvgın, S., & Eser, B. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1682-8 · Cited by 27
Mucormycosis of the Head and Neck
Dan, M. (2011) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0162-8 · Cited by 27
Leal, S. M., Roy, S., Vareechon, C., Carrion, S. D. J., Clark, H., López‐Berges, M. S., Pietro, A. D., Schrettl, M., Beckmann, N., Redl, B., et al. (2013) · PLoS Pathogens · doi:10.1371/annotation/4f388450-90fe-4c65-9b9b-71a2b7935ac0 · Cited by 27
Invasive Mold Infections in Solid Organ Transplant Recipients
Crabol, Y., & Lortholary, O. (2014) · Scientifica · doi:10.1155/2014/821969 · Cited by 26
“Indeed, the iron chelator deferasirox protects mice from mucormycosis and enhanced the efficacy of liposomal amphotericin B [119].”
BackgroundWorkman, D. G., Hunter, M., Dover, L. G., & Tétard, D. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.04.018 · Cited by 26
Mucormycosis: The hidden and forgotten disease
Darwish, R. M., Almasri, M., & Almasri, M. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15487 · Cited by 25
“, 2009) Costly DFX plus lipid polyene 20 mg kg−1 po qd for 2– 4 weeks in vitro good fungicidal activity against Mu rocule (Ibrahim et al., 2007); synergism with Lam B in murine model of mucormycosis (Ibrahim et al.”
BackgroundInfluentialHierro e infección fúngica invasiva
Álvarez, F., Fernández‐Ruiz, M., & Aguado, J. M. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.04.002 · Cited by 25
Schulze, B., Rambach, G., Schwartze, V. U., Voigt, K., Schubert, K., Speth, C., & Jacobsen, I. D. (2017) · Virulence · doi:10.1080/21505594.2017.1360460 · Cited by 25
Mucormycosis and Entomophthoramycosis (Zygomycosis)
Ibrahim, A. S., Edwards, J. E., Filler, S. G., & Spellberg, B. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_15 · Cited by 25
Self-citationMucormycosis pathogenesis: Beyond Rhizopus
Spellberg, B. J. (2017) · Virulence · doi:10.1080/21505594.2017.1364335 · Cited by 25
Self-citationCandoni, A., Aversa, F., Busca, A., Cesaro, S., Girmenia, C., Luppi, M., Rossi, G., Venditti, A., Nosari, A., & Pagano, L. (2014) · Journal of Chemotherapy · doi:10.1179/1973947814y.0000000224 · Cited by 24
Chakrabarti, A., & Singh, S. (2020) · Current Fungal Infection Reports · doi:10.1007/s12281-020-00406-2 · Cited by 24
Stanford, F. A., Matthies, N., Cseresnyés, Z., Figge, M. T., Hassan, M. I. A., & Voigt, K. (2021) · Journal of Fungi · doi:10.3390/jof7040272 · Cited by 23
“As such, there remains the possibility of applying iron chelators as adjunctive therapy strategies as exploring this avenue could limit or inhibit fungal growth [11,36,43].”
BackgroundIron Chelation Therapy in Myelodysplastic Syndromes
Messa, E., Cilloni, D., & Saglio, G. N. (2010) · Advances in Hematology · doi:10.1155/2010/756289 · Cited by 23
“In contrast, it has been demonstrated that deferasirox can be effective against mucormicosis infection in vivo [45].”
BackgroundMetal Ions and Infectious Diseases. An Overview from the Clinic
Carver, P. L. (2013) · Metal ions in life sciences · doi:10.1007/978-94-007-7500-8_1 · Cited by 22
Pseudomonas Synergizes with Fluconazole against Candida during Treatment of Polymicrobial Infection
Hattab, S., Dagher, A.-M., & Wheeler, R. T. (2022) · Infection and Immunity · doi:10.1128/iai.00626-21 · Cited by 22
Deferasirox limits cartilage damage following haemarthrosis in haemophilic mice
Roosendaal, G., Mastbergen, S. C., Coeleveld, K., Biesma, D. H., Lafeber, F. P. J. G., Schutgens, R. E. G., & Nieuwenhuizen, L. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-01-0029 · Cited by 22
“In addition, and comparable to the human situation, deferasirox was found to be effective in reducing murine iron levels in plasma and in several tissues (17, 23).”
BackgroundIron acquisition inLeishmaniaand its crucial role in infection
NIU, Q., Li, S., Chen, D., CHEN, Q., & Chen, J. (2016) · Parasitology · doi:10.1017/s0031182016000858 · Cited by 21
Genetic Transformation of Zygomycetes Fungi
Papp, T., Csernetics, Á., Nyilasi, I., Ábrók, M., & Vágvölgyi, C. (2010) · Springer eBooks · doi:10.1007/978-90-481-3713-8_3 · Cited by 21
“green fluorescent protein Ibrahim et al., 2007b gene (gfp)”
BackgroundMethodNovel Approaches in the Management of Mucormycosis
Lamoth, F. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00463-3 · Cited by 20
Ting, J. Y., Chan, S.-Y., Lung, D. C., Ho, A. C.-C., Chiang, A., Ha, S., Tsoi, N. N.-S., & Chan, G. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181e622bf · Cited by 20
“In fact, both chelators have demonstrated the ability to protect mice models from developing mucormycosis probably by depleting the iron supply to the microbials.(18,19) Reed et al(20) reported a case of advanced and progressive brainstem and cavernous sinus mucormycosis not responding to antifungal agent combinations…”
BackgroundWu, H., Yang, L., Chen, L., Xiang, F., & Gao, H. (2017) · Analytical Methods · doi:10.1039/c7ay01917c · Cited by 20
Iron chelation therapy as a treatment for Pythium insidiosum in an animal model
Zanette, R. A., Alves, S. H., Pilotto, M. B., Weiblen, C., Fighera, R. A., Wolkmer, P., Flores, M. M., & Santúrio, J. M. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks534 · Cited by 20
Mucormycosis: a new concern in the transplant ward?
Robin, C., Alanio, A., & Cordonnier, C. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000082 · Cited by 19
“Because of the role of iron overload in the occurrence of mucormycosis, and of the animal data showing the benefit of combining L-AmB and deferasirox [77], a randomized, double-blinded trial, the Deferasirox–AmBisome Therapy for Mucormycosis study, compared the combination of L-AmB with either deferasirox or placebo i…”
Metal Acquisition and Homeostasis in Fungi
Bailão, E. F. L. C., Parente, A. F. A., Parente, J. A., Bailão, M. G. S., de Castro, K. P., Kmetzsch, L., Staats, C. C., Schrank, A., Vainstein, M. H., Borges, C. L., et al. (2012) · Current Fungal Infection Reports · doi:10.1007/s12281-012-0108-8 · Cited by 19
The reversed halo sign as the initial radiographic sign of pulmonary zygomycosis
Busca, A., Limerutti, G., Locatelli, F., Barbui, A. M., Rosa, F. G. D., & Falda, M. (2011) · Infection · doi:10.1007/s15010-011-0156-y · Cited by 19
Adams, R., & Bird, R. J. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620712472355 · Cited by 19
“Although there are some data that deferasirox may have potential as an adjunct therapy in patients with mucormycosis [Ibrahim et al. 2007], a recent prospective trial failed to show benefit for deferasirox in combination with standard treatment as upfront therapy [Spellberg et al. 2012].”
ResultOpportunistic and Systemic Fungi
Kosmidis, C., & Denning, D. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00189-1 · Cited by 20
How metals fuel fungal virulence, yet promote anti-fungal immunity
Alselami, A., & Drummond, R. A. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.050393 · Cited by 18
“Now, other types of iron chelators, which do not provide siderophore-mediated uptake to the fungus, have been shown to improve survival when used adjunctively with antifungal drugs in mouse models of mucormycosis (Ibrahim et al., 2007).”
Hepatic mucormycosis with abscess formation
Su, H. K., Thompson, G. R., & Cohen, S. H. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.02.021 · Cited by 18
“These findings have prompted interest in the use of other iron chelators such as deferasirox and deferiprone, neither of which supplies iron to the Mucorales and which are fungicidal in vitro (Ibrahim et al., 2007).”
BackgroundEmergence of the Molds Other than Aspergillus in Immunocompromised Patients
Arif, S., & Perfect, J. R. (2017) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2017.04.014 · Cited by 18
Haidar, G., & Singh, N. (2018) · Transplantation · doi:10.1097/tp.0000000000002353 · Cited by 18
Mucormycosis: A Rare disease to Notifiable Disease
Panda, S., Sahu, M. C., Turuk, J., & Pati, S. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-024-01315-z · Cited by 17
“[ 83] The CotH present on the spore germlings get interacted to over expressed GRP78 and helps in tissue invasion.”
Actualización en terapia antifúngica: nuevos fármacos e indicaciones
Fortün, J. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(11)70042-8 · Cited by 17
Immunotherapy of infections caused by rare filamentous fungi
Katragkou, A., & Roilides, E. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03689.x · Cited by 17
“In addition, deferasirox undergoes a synergistic interaction with liposomal amphotericin B and enhances the host inflammatory response against zygomycetes [45].”
BackgroundChitasombat, M. N., & Niparuck, P. (2018) · Infectious Disease Reports · doi:10.4081/idr.2018.7765 · Cited by 17
“Aspartate aminotransferase (U/L) 29 (7-119) 31 (11-50) 63 (20-99)”
Lethargy and vision loss: successful management of rhinocerebral mucormycosis
Mulki, R., Masab, M., Eiger, G., & Perloff, S. R. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-215855 · Cited by 17
Developments in identifying and managing mucormycosis in hematologic cancer patients
Pagano, L., Dragonetti, G., Carolis, E. D., Veltri, G., Principe, M. I. D., & Busca, A. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1796624 · Cited by 16
Soliman, S. S. M., El‐labbad, E. M., Abu-Qiyas, A., Fayed, B. E., Hamoda, A. M., Al-Rawi, A. M., Dakalbab, S., El‐Shorbagi, A., Hamad, M. A., Ibrahim, A. S., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.863133 · Cited by 16
Self-citationAlmyroudis, N. G., & Segal, B. H. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.141 · Cited by 16
Combination antifungal therapy: From bench to bedside
Wirk, B. M., & Wingard, J. R. (2008) · Current Infectious Disease Reports · doi:10.1007/s11908-008-0076-x · Cited by 16
Valković, T., & Stanić, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154457 · Cited by 15
“showed that the iron chelator deferasirox protects the kidneys of mice from mucormycosis through iron starvation [83].”
BackgroundHost Sensing by Pathogenic Fungi
Sherrington, S. L., Kumwenda, P., Kousser, C., & Hall, R. A. (2017) · Advances in applied microbiology · doi:10.1016/bs.aambs.2017.10.004 · Cited by 14
Rhino-orbito-cerebral mucormycosis and its resurgence during COVID-19 pandemic: A review
Karkhur, S., Soni, D., Chauhan, K., Sarkar, D., Gautam, M., Verma, S., Nyodu, R., Yadav, N. S., & Sharma, B. B. (2022) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1219_22 · Cited by 13
“[54] In an animal study on mice, Ibrahim et al.[54] demonstrated that deferasirox, an iron chelator, synergistically improved survival and reduced tissue‐mucor burden when combined with liposomal amphotericin B.”
BackgroundZanette, R. A., Bitencourt, P. E. R., Kontoyiannis, D. P., Fighera, R. A., Flores, M. M., Kommers, G. D., Silva, P. S., Ludwig, A., Moretto, M. B., Alves, S. H., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118932 · Cited by 13
“Therefore, it was hypothesized that this drug would be of interest in patients with pythiosis in view of its iron chelating and immunomodulatory properties [2, 11].”
BackgroundResultInfluentialMucormycosis in diabetes mellitus
Khatiwada, P., Giri, A., & Khatiwoda, P. (2012) · Journal of Advances in Internal Medicine · doi:10.3126/jaim.v1i2.6531 · Cited by 13
Intracerebral hemorrhage in a patient with Churg-Strauss syndrome
Prabhakar, S. K., Mishra, S. K., Das, C., & Das, A. K. (2007) · Neurology India · doi:10.4103/0028-3886.37102 · Cited by 13
Role of Iron Chelators in Mucormycosis
Medhi, B., Mahalmani, V., Sarma, P., & Prakash, A. (2021) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_604_21 · Cited by 13
“[20] According to Reed et al ., a diabetic aged 40 years presented with aggressive zygomycosis who despite being started with a combination of high‑dose liposomal amphotericin B and caspofungin and surgical debridement progressed with central nervous system involvement.”
Rise of mucormycosis during the COVID-19 pandemic and the challenges faced.
Kottarathil, M., Premamalini, T., Sathyamurthy, P., & Kindo, A. J. (2023) · PubMed Central · doi:10.18502/cmm.2023.345032.1400 · Cited by 12
Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19
Sharma, N., Wani, S. N., Behl, T., Singh, S., Zahoor, I., Sehgal, A., Bhatia, S., Al‐Harrasi, A., Aleya, L., & BUNGAU, S. G. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-24032-2 · Cited by 12
Patient With Abdominal Pain-Concealing Gastrointestinal Mucormycosis.
Azhar, A., Calubiran, O. V., Kilaru, R., Lincoln, J. A., Moshenyat, I., Basti, K., & Visconti, E. B. (2009) · PubMed · Cited by 12
Metadata
- Authors
- Ibrahim, A. S., Gebermariam, T., Fu, Y., Lin, Husseiny, M. I., French, S. W., Schwartz, J., Skory, C. D., Edwards, J. E., & Spellberg, B. J.
- Affiliations
- University of California, Los Angeles (US)
- Charles River Laboratories (United States) (US)
- National Center for Agricultural Utilization Research (US)
- Corresponding author
- Ibrahim, Ashraf S.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2007-09-04
- Volume
- 117
- Issue
- 9
- Pages
- 2649-2657
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1957543
- OpenAlex
- W2113977119
- Cited by
- 308
- References
- 43
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 21 · 2020: 15 · 2019: 12 · 2018: 12 · 2017: 12 · 2016: 12 · 2015: 15 · 2014: 20 · 2013: 23 · 2012: 25
- FWCI
- 13.63
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- National Institute of Allergy and Infectious Diseases (R01 AI63503-01A2, R01AI019990, K08AI060641, AI-063382, R01-AI19990, R21AI064716, R01AI063382, R01AI063503)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- mucormycosis, deferasirox, iron chelation, iron starvation, Mucorales, Rhizopus oryzae, liposomal amphotericin B, antifungal therapy, diabetic ketoacidosis, neutropenia, host inflammatory response, serum iron, adjunctive therapy
- MeSH terms
- Deferasirox, Amphotericin B, Animals, Benzoates, Diabetes Mellitus, Drug Therapy, Combination, Iron, Iron Chelating Agents, Liposomes, Male, Mice, Inbred BALB C, Mucorales, Mucormycosis, Triazoles, Survival Rate, Th1 Cells, Th2 Cells, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.